MedDataX Logo

Where Did the Authors Work When They Conducted Their Clinical Pharmacology Studies?

NCT ID: NCT07115680

Last Updated: 2025-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

503 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-15

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is unknown in which countries the clinical pharmacology studies published in leading specialized journals were conducted. The hypothesis is that studies in this specialty tend to be conducted and published by authors from a single country. This analysis aims to describe the number of collaborators and the countries in which they worked, using the Nature Index concept of "share."

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Original articles (full reports, short communications, research letters) on human participants, data, or material published in the seven top (as per Journal Citations Report 2024 Impact Factor) clinical pharmacology hybrid journals linked to clinical pharmacology professional societies will be included. Articles of interest to be included from the June 2025 issue backwards until reaching 100 articles or until the January 2024 issue, whichever comes first. The country of the main authors (first author/last author) and the countries where all the contributors listed in the article's byline worked will be recorded. Collaboration index and degree of collaboration will be calculated. The contribution of all countries will be calculated using the Nature index's "share" concept.Depending on whether a high percentage of articles are written by authors from the same country as a given journal (and scientific society), the need to adjust the results to reflect a situation closer to reality in terms of the importance of different countries in the publication of the articles evaluated will be assessed. As a proxy, the relevance of each country in contributing to clinical pharmacology research will be calculated by multiplying the "share" score by the JCR impact factor of each journal and adding the scores obtained from the seven journals. In addition, In addition, following slightly modified terminology used by ClinicalTrials.gov, the type of sector (industry, government institutions, and 'Others') will also be recorded to help characterize the studies evaluated. However, the 'Others' category will be classified into hospitals, universities, and research centers. Funding will be recorded as public, private, and public-private.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Scientific Collaboration in Clinical Pharmacology

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Clinical pharmacology, studies on humans, recently published

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single-country studies

Multinational studies

human participants, data or material

Intervention Type OTHER

Articles on human participants, data, or material published in top (as per JCR IF) clinical pharmacology journals linked to professional societies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

human participants, data or material

Articles on human participants, data, or material published in top (as per JCR IF) clinical pharmacology journals linked to professional societies

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Articles on human participants, data or material. Original articles, short reports, research letters.

Exclusion Criteria

* In vitro studies, animal studies. Editorials, letters, commentaries, perspectives.
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rafael Dal-Re, MD, PhD, MPH

Role: PRINCIPAL_INVESTIGATOR

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Health Research Institute Fundación Jiménez Díaz

Madrid, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IIS-FJD-RDR-2025-001

Identifier Type: -

Identifier Source: org_study_id